You are here

Article Text

Article menu
Download PDFPDF
LETTER
Osteogenesis imperfecta and intravenous pamidronate
  1. I Banerjee1,
  2. G J Shortland1,
  3. W D Evans1,
  4. J W Gregory2
  1. 1Department of Child Health, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK; ibanerjee@freeuk.com
  2. 2University of Wales, College of Medicine, Heath Park, Cardiff CF14 4XN, UK

https://doi.org/10.1136/adc.87.6.562-a

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Osteogenesis imperfecta (OI) is a chronic, disabling condition in which treatment with cyclical intravenous treatment with pamidronate can be useful for symptom relief,1 despite questions about long term safety.2 A recent study3 in this journal showed a decrease in bone turnover and gradual increase in bone density measurements without significant side effects, following such treatment in children affected with OI.

    We wish to report our own experience …

    View Full Text